Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMARETTO: SC Infliximab in IBD
NCT06113913Phase 4Recruiting
- Sponsor
- Belgian IBD Research and Development
- Start
- Apr 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of infliximab in inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis (UC) (3 arms), sponsored by Belgian IBD Research and Development. Primary endpoint: Proportion of patients that maintain steroid-free clinical and biological remission without treatment optimization at 52 weeks. Started Apr 2024; status: recruiting.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06113913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06113913.